DR. Michael R. BUCHANAN

Michael R. BUCHANAN
Professor,
Department of Pathology & Molecular Medicine
McMaster University,

HSC-2N22c
1200 Main St West
Hamilton, Ontario L8N 3Z5
Telephone: (905) 525-9140 ext 22930
E-mail <mbuchan@mcmaster.ca>

88 Farnham Avenue
Toronto, Ontario, Canada
M4V 1H4
Telephone: (416) 716 3167
E-mail <lakestonehouse@sympatico.ca>

B.A. (Honours Psychology) University of Toronto 1970
M.Sc. (Medical Sciences) McMaster University 1974
Ph.D. (Medical Sciences) McMaster University 1978
Post-Doctoral Fellow Harvard University 1980

Professor, McMaster University

Director of Surgical Research, Hamilton Civic Hospitals
Associate Professor, Department of Surgery, McMaster University

Senior Scientist, Hamilton Civic Hospitals Research Centre

Associate Professor, McMaster University

Career Investigator, Canadian Heart Foundation

Assistant Professor McMaster University
Health Sciences Centre, Department of Pathology

1 Research Associate, Harvard University
Peter Bent Brigham Hospital, Boston, Mass

Research Fellow with Dr. R. Cotran,
Harvard Medical School, Boston, Mass

Canadian Heart Research Scholar,
McMaster University Health Science Centre
Department of Pathology

Research Fellow (Dr. J. Hirsh), McMaster University,
Department of Pathology

Research Assistant (Dr. J. Hirsh), McMaster University
Department of Pathology

CIHR: New Frontiers Program - Task Force for the Development of Research a Agenda for Cardiovascular Disease in Women.
(Brister, Turek, Buchanan et al).
$30,000.

ISTH Sanofi Travel Award - Sanofi Finalist Award

HSFO Restenosis and Acute antithrombotic Therapy. (Buchanan, Brister) $72,908.

HSFO Cardiopulmonary bypass and antithrombotic therapy. ( Brister, Buchanan) $30,000.

OHSF Dermatan Sulfate in Cardiopulmonary Bypass (Brister, Buchanan) $75,000.

MRC Regulation of endothelial vitronectin receptor and its effect on cancer cell adhesion and metastasis. (Orr, Podor, Buchanan) $145,200.

OHSF Special Equipment Grant #E2480 (Buchanan) $20,000.

OHSF. Blood Cell/Vessel Wall Interactions: Basic and Applied Studies. (Buchanan, Brister, Haas) $120,000/yr.

OHSF. Dermatan Sulfate in Cardiopulmonary Bypass. (Brister, Ofosu, Buchanan) $67,000.

III Sanofi Thrombos Prix. International Society Thrombosis/ Haemostasis. Participation of Leukocytes in Thrombo-Embolism. Awarded in Toyko, Japan. August, 1989.

OHSF. Career Investigator Personal Award.

OHSF. Fatty acid Metabolism and Platelet Vessel Wall Interaction (Buchanan, Hirsh) $140,000/yr.

MRC Grant. Regulation of cancer metastasis by endothelial cells. (Orr, Buchanan, Podor) $60,000/yr.

OHSF Grant. Biological Significance of No Affinity Heparin. (Young, Hirsh, Buchanan, 2 years) $40,000/yr.

MRC Grant, Lipoxygenase Metabolites act as Internal Regulators of Cell/Cell Adhesion.(Buchanan, Bastida, 3 years) $60,000/yr.

MRC Grant. Regulation of Interaction between endothelium and tumor cells. (Orr, Buchanan, 2 years) $60,000/yr.

MRC Grant (T). Basic and Applied Studies with Low Molecular Weight Heparins. (Hirsh, Buchanan, Ofosu, 5 years) $160,000/yr.

MRC Visiting Scientist for Dr. N. Blaes (1 year)

Canadian Heart Research Associateship

NATO Travel Grant (M. Lagarde, Lyon France, H. Chap, Toulouse France, Co-Investigators, 2 years)

Medical Research Council Term Grant (Hirsh, Buchanan, Ofosu, 3 years)

Ontario Heart and Stroke Foundation Term Grant (Buchanan, Hirsh, 3 years)

Ontario Heart Term Grant (Hirsh, Buchanan, 3 years)

Canadian Heart Research Scholarship; Ontario Heart Grant-in-Aid (Buchanan)

Ontario Heart Fellowship

XVIII Congress 1STH - Scientific Review Committee - Birmingham

XVII Congress 1STH - Scientific Review Committee - Paris

MRC Scientific Committee - Experimental Medicine

XIV Congress 1STH - Scientific Review Committee - Jerusalem

XIII Congress ISTH - Scientific Review Committee -Amsterdam

International Scientific Organizing Committee: VI Int'l Symposium on the Biology of the Vascular Endothelium

XII Congress ISTH - Scientific Review Committee, Tokyo, Japan.

Advisory Committee, Int'l. Cong. Prostaglandins: Related Compounds

Canadian Atherosclerosis Soc. Education Committee, Ottawa, Canada.

Canadian Heart Scientific Review Committee

Working Group on the Role of the White Blood Cell in Ischemia (Royal Society of Medicine, London, England)

Chairman, Scientific Executive Committee on Vth. International Symposium on the Biology of the Vascular Endothelium (Toronto, Canada 1988)

Scientific Review Committee: XIth Int'l. Congr. Thromb. Haemost. Brussels, Belgium.

Scientific Executive Committee International Workshop on the Development and Therapeutic Use of Antithrombotic, Antimetastatic and Fibrinolytic Compounds. Montebello, Quebec.

VIIIth Int'l. Congr. Thromb. Haemost. Scientific Committee, Toronto, Canada.

Canadian Heart Scientific Review Committee

Learning Assistance Triage

Chair, Policies & Procedures committee, MD Undergraduate Admissions.

MD Undergraduate Programme “Tutor Doctor”

Chair, Learning Assistance Programme

International Medical Admissions Team, Riyadh, Saudi Arabia

Chair, MD Undergraduate Remedial Program

MD Undergraduate Student Affairs Committee

Hamilton Civic Hospitals - Planning & Development Committee - HGH Research Centre

Hamilton Civic Hospitals - Executive Research Committee

Chair, McMaster University Dept. of Surgery, Education Research Committee,

Hamilton General Hospital Space Sub-Committee

Department of Surgery Academic Research Review Committee

Executive Committee of Hamilton Civic Hospital Research Centre

Hamilton Civic Hospitals Institutional Review Board

Regional Hematology Advisory Committee, Active Member

Department of Pathology Faculty Association Representative (elected)

CSD Equipment Sub-committee

Fellow, American Heart Association (F.A.H.A)

Canadian Cardiovascular Society

International Society for the Study of Fatty Acids and Lipids (ISSFAL)

International Society Applied Cardiovascular Biology

Fellow, Royal Society of Medicine

Canadian Atherosclerosis Society

New York Academy of Sciences

Int'l Soc Thromb Haemost - Animal Model Subcommittee - Advisor

American Heart Association, Council of Thrombosis

Co-chairman, Symposium on "A Pharmacokinetic and Pharmacodynamic Approach to Antithrombotic Therapy,Toronto, Canada

International Society on Thrombosis and Haemostasis

Tissue Culture Association

Atherioscl Vasc Biol
*Atherosclerosis
*Blood
Brit J Haematology
Clinical Investigative Medicine
*Can L Cardiol
Cancer Research
*Circ*Haemostasis
Int'l J Cancer
Life Sciences
New England J Medicine
*Prostaglandins
*Thrombosis Haemostasis
*Thrombosis Research

Wiener Klinische Wochenschrift - Editorial Board

Thrombosis and Hemorrhagic Disorders - Editor

Haemostasis - Editorial Board

Lecturer: Blood and Cardiovascular Diseases. Graduate Program MS732

Tutor: Unit II Medical Students
Unit III Medical Students

Education Program - Tutor Workshop

Chair: MD Undergraduate Remedial Program

Chair: Medical School Admissions - Personal Interviews

Collation: Medical School Admission

PI Interviewer: Medical School Admissions

Tutor: Cell Biology Enquiry 2K03

OHF Fellow, Roberto Braude MD

MRC - Postdoc Fellow, Francoise Fernandez PhD

Can Ext Affairs Award Fellow, Giancarlo Agnelli MD

MSc Student, Joanne Van Ryn BSc

Research Fellow, Philippe N'guyen MD

Ph.D. Grad. Student, Thomas A Haas. B.Sc.

Post Doctoral Fellow: Davide Lauri, M.D

Post Doctoral Fellow: Elisabetta Weber, M.D.

Clinical Fellow - Wes Oczkowski, M.D.

Post Doctoral Fellow, Maria-Cruz Bertomeu, M.D.

Ph.D. Supervisory Committee, Steven Shaughnessy, M.Sc.

Foreign Grad Student, Filomenia Salvia, M.D.

Postgraduate fellow - Lu Cai, M.D.

Ph.D. Grad. Student, Rob LaFrenie, B.Sc.

Post Doctoral Fellow, Vincent Riambau, M.D.

Clinical Fellow - Patrick Brill-Edwards, M.D.

Clinical Fellow - Don Houston, M.D., Ph.D.

Post Doctoral Fellow, Peng Liao, M.D.

Clinical Fellow - Carlos Fontevila

MSc Grad Student - Kyle Buchard

Anne Boyle, Medical Program

E. Chernick, Medical Program

Jose Silveiri, Medical Program

Dan Somogyi, Medical Program

Catherine Munn, Medical Program

Markus Bischoff, Medical Program

Tom Spaxman, Medical Program

(April) PhD Examiner - Adel B Elmoselhi, Medical Sciences Program

(Oct) PhD Examiner - Ted Watson, Medical Sciences Program

Summer student supervisor - Glenn Maclean, Medical Sciences Program

May - Aug Summer student co-supervisor- Robin Varghese - Medical Sciences (Univ Western)
- Steven Daunt - Medical Sciences (U of T)

Clinical Fellow – Gilbert Tang, MD (co-supervisor, U of T).

Clinical Fellow – Mohamed J Albanna, MD (co-supervisor, U 0f T).

Student Affaires Accreditation subcommittee

MD Admissions Revisions Subcommittee member.

Student Affairs, MD Undergraduate Program

Personal Interview Working Group

Chair, Medical School Admission, Personal Interviews

Medical School Admissions - Collation

1. Completion of "Isolation & Culture of Blood Vessel Derived Cells" course of The W. Alton Jones Cell Science Centre, Lake Placid, *Sept., 1981.

2. Completion of Workshop 1, "Role of the Tutor in Small Group Learning", McMaster University, May, 1982.

3. Completion of "A Practical Course in Liquid Chromatography", Waters Scientific, Toronto, May, 983.

4. Completion of Workshop 2, "Design of Evaluation Tools of Systems", McMaster University, May, 1983.

5. Faculty Development Program for Leadership Roles in Education. 1983-1984.

P U B L I C A T I O N S

Buchanan MR, Brister SJ. Inhibition of intimal hyperplasia after 13-HODE treatment following vessel wall injury. To be submitted .

Buchanan MR, Brister SJ, Cardin AD.Synergistic inhibition of thrombin-induced platelet aggregation by [Intimatan + Integrilin]: Implications for their clinical use. To be submitted.

142 Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: A review. Intensive Care Med 30: 1873-1881, 2004.

141 Wang C-H, Stanford WL, Weisel RD, Li S-H, Szmitko PE, Fedak PWM, Brister SJ, Buchanan MR, Li R-k Mickle DAG, Yau TM, Verma S. Stem cell factor plays a critical role in neointimal formation by bone marrow derived progenitor cells. Lancet.

140 Brister SJ, Schwartz L, Bourassa MG, Peniston CM Buchanan MR. There is no need to stop aspirin antiplatelet therapy before elective or non-urgent coronary artery bypass grafting. Submitted to Ann Thoracic Surgery

139 Van Ryn J, Lorenz M, Merk H, Buchanan MR, Eisert WG. Accumulation of radiolabelled-platelets and –fibrin on the carotid artery of rabbits after angioplasty: Effects of heparin and dipridamole. Thromb Haemost 90: 1179-86, 2003.

138 Verma S, Buchanan MR, Anderson TJ. Endothelial function as a biomarker of vascular disease. Circ 108: 2054-2059, 2003.

137 Brister SJ, Ivanov J, Buchanan MR. Reoperative coronary artery bypass surgery in women: analysis of risks and benefits. J Thorac Cardiovasc Surg, In Press, 2003.

136. Ibrahim MF Paparella D, Ivanov J, Buchanan MR, Brister SJ. Sex is a risk for morbidity and mortality during combined valve and coronary surgery. J Thorac Cardiovasc Surg 126: 959-964, 2003.

135. Buchanan MR, Maclean GA, Brister SJ. Selective and sustained inhibition of thrombin activity by Intimatan. Thromb Haemost 86: 909-913, 2001.

134. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston CM on behalf of the BRAT Investigators.
Results of the BRAT Study - benefits and risks of aspirin on thrombosis in patients undergoing coronary artery bypass - Lack of an aspirin effect. Can J Cardiol 16: 1385-1390, 2000. Funded by discretionary funds from 3 institutions.

133. Buchanan MR and Brister SJ. Anticoagulant and antithrombotic properties of Intimatan, a heparin cofactor II agonist. Thromb Res 99: 603 - 612, 2000.
HSFO

132. Buchanan MR.. GPA, academic background and knowledge deficits of students in a self-directed problem-based learning environment. Pedagogue 9: 2, 1999.

131. Brister SJ, Pelletier A, Fedorshyn J, Puchalski S, Buchanan MR. Cardiopulmonary bypass pumps
and thrombin generation: What goes around comes around. ASAIO J 44: 794 - 798, 1998. OHSF

130. Buchanan MR, Brister SJ. Inhibition of chronic vessel wall (re)stenosis with acute thrombin inhibition:
Relative effects of heparin and dermatan sulphate. Thromb Res 91: 157 - 167, 1998. HSFO

129. Schwartz L, Brister SJ, Bourassa MG, Peniston C, Buchanan MR on behalf of the BRAT Investigators. Interobserver reproducibilty and biological variability of the Surgicutt II Bleeding Time. J Thromb Thrombolysis.6: 155 - 158, 1998. (UNFUNDED)

128. Buchanan MR, Horsewood P, Brister SJ. Regulation of endothelial cell/ and platelet/receptor-ligand binding by the 12- and 15-lipoxygenase monohydroxides, 12-, 15-HETE and 13-HODE. Prostaglandins Leukot Essent Fatty Acids 58: 339 - 346, 1998. HSFO

127. Cortelazzo S, Marchetti E, Orlando A. Falanga A, Barbui T, Buchanan MR. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: Role of the lipoxygenase pathway. Am J Hematol 57: 277 - 282, 1998. HSFO

126. Buchanan MR, Brister SJ. Effects of 13-HODE and other monohydroxides on integrin/ligand binding: Implications for cell cell interactions. Adv Exp Med Biol 433: 265-269, 1997. OHSF

125. Brister S.J, Buchanan MR. Effects of linoleic acid and/or marine oil supplements on vessel wall thromboresistance in patients undergoing cardiac surgery. Adv Exp Med Biol 423: 275-278, 1997. OHSF

124. Gimenez-Arnau A, Barranco C, Alberola M. Wale C, Serrano S, Buchanan MR, Camarasa JG. Effects of linoleic acid supplements on atopic dermatitis. Adv Exp Med Biol 433: 285 - 289, 1997. OHSF

123. Low AM, Berdik M, Sormaz L, Gataiance S, Buchanan MR, Kwan CY, Daniel EE. Plant alkalloids, tetrandrine and hernandezine, inhibit calcium-depletion stimulated calcium entry in human and bovine endothelial cells. Life Sci 58: 2327-2335, 1996. HSFO

122. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 11: 221 - 227, 1995. OHSF

121 Brister SJ, Buchanan MR. Heparinless cardiopulmonary bypass (CP) revisited: A newer strategy to avoid CPB/heparin related bleeding. J Cardiothorac Vasc Anesth 9: 317 -321, 1995. OHSF

120. Lafrenie RM, Gallo S, Podor TJ, Buchanan MR, Orr FW. The relative roles of vitronectin receptor, E-selectin and VCAM-1 in cancer cell adhesion to interleukin-1-treated endothelial cells. Eur J Cancer 30A: 2151-2158, 1994. MRC

119. Wells J, Nicosia S, Wale C, Smith LJ, Buchanan MR. Thrombin generation in patients undergoing carotid endarterectomy: Implications in acute vessel wall closure and antithrombotic therapy. Thromb Res 75: 419-426, 1994. OHSF

118. Buchanan MR, Liao P, Smith LJ, Ofosu FA. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: Importance of the heparin cofactor II. Thromb Res 74: 463-475, 1994. OHSF

117. Brister SJ, Ofosu FA, Heigenhauser GJF, Gianese F, Buchanan MR. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemost 71: 468-473, 1994. OHSF

116. Zhang H, Inazu M, Weir B, Buchanan MR, Daniel EE. Cyclopiazonic acid stimulates calcium influx through non-specification channels in endothelial cells. Eur J Pharmacol 251: 119-125, 1994. OHSF

115. Houston DS, Buchanan MR. Influence of endothelium-derived relaxing factor on platelet function and hemostasis in vivo. Thromb Res 74: 25-37, 1994. OHSF

114. Lafrenie RM, Buchanan MR, Orr FW. Adhesion molecules and their role in cancer metastasis. Cell Biophys 23: 3-89, 1993.

113. Hamilton M, Macdonald W, Levely A, Brister SJ, Buchanan MR. A rose is a rose - or is it? Compedium Can Soc Clin Perf: 47-49, 1993.

112. Hernandez R, Alemany M, Bozzo J, Buchanan MR, Ordinas A, Bastida E. Platelet adhesivity to subendothelium is influenced by polymorphonuclear leukocytes: Studies with aspirin and salicylate. Haemostasis 23: 1-7, 1993. OHSF

111. Bertomeu MC, Gallo S, Lauri D, Haas TA, Orr FW, Bastida E, Buchanan MR. Interleukin 1-induced cancer cell/endothelial cell adhesion in vitro and its relationship to metastasis in vivo: role of vessel wall 13-HODE synthesis and integrin expression. Clin Expt Metastasis 11: 243-250, 1993. MRC

110. Buchanan MR, Bertomeu MC, Haas TA, Orr FW, Eltringham-Smith LJ. Localization of 13-HODE and the vitronectin receptor in human endothelial cells and subsequent in vitro endothelial cell platelet interactions. Blood 81(12): 3303-3312, 1993. OHF

109. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery. Is heparin the ideal anticoagulant? Thromb Haemost 70(2): 259-263, 1993. OHSP

108. Van Ryn-McKenna J, Merk H, Muller TH, Buchanan MR, Eisert WH. The effects on heparin and annexin V on fibrin accretion after injury in the jugular veins in rabbits. Thromb Haemost 69:227-237, 1993. MRC/OHSF

107. Hamilton M, MacDonald W, Levely A, Brister SJ, Buchanan MR. A rose is a rose - or is it? 1993 Compendium Can Soc Clin Perfusion: 47-49, 1993

102. Bastida E, Almirall L, Ordinas A, Buchanan MR, Orr FW, Bertomeu M-C, Haas TA. Effects of endothelial cell treatment on 13-HODE and prostacylin synthesis and its correlation with tumor cell-vascular endothelial cell adhesion. Invasion Metastasis 11: 273-280, 1991. MRC

101. Okwusidi JI, Anvari N, Kulczycky M, Blajchman MA, Buchanan MR, Ofosu FA. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. J Lab Clin Med 117: 359-364, 1991 MRC.

100. Hirsh J, Buchanan MR. Comparative effects of heparin and LMW heparin on hemostasis. Thromb Res, Suppl. XIV: 11-17, 1991. MRC

99. Shaughnessy SG, Lafrenie RM, Buchanan MR, Ofosu, F.A. Endothelial cell damage by Walker carcinoma cells is dependent upon tumour cell adhesion. Am J Pathol 138: 1535-1543, 1991. MRC

98. Aznar-Salatti J, Bastida E, Haas TA, Escolar G, Ordinas A, de Groot PHG, Buchanan MR. Platelet adhesion to exposed endothelial cell extracellular matrixes is influenced by the method of preparation. Arteriosclerosis 11: 1-7, 1991. OHSF

106. Lafrenie RM, Podor TJ, Buchanan MR, Orr FW. Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. Cancer Res 52: 2202-2208,1992. MRC

105. Brill-Edwards P, Van Ryn-McKenna J, Cai L, Ofosu FA, Buchanan MR. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. Thromb Haemost 68: 424-427, 1992. MRC

104. Van Ryn-McKenna J, Ofosu FA, Buchanan MR. The effects of heparin and dermatan sulfate on tPA- induced thrombolysis. Fibrinolysis 6: 1-7, 1992. OHSF

103. Ofosu FA, Fenton JW, Maraganore J, Blajchman MR, Yang X., Smith L, Anvari, N, Buchanan MR, Hirsh J. Inhibition of the amplification reaction of blood coagulation by site-specific inhibitors of "-thrombin. Biochem J 283: 893-897, 1992. MRC

97. Brister SJ, Haas TA, Bertomeu M-C, Austin J, Buchanan MR. 13-HODE synthesis in internal mammary arteries and saphenous veins: Implications in cardiovascular surgery. Adv Prostaglandin Thromboxane Leukot Res 21: 667-670, 1990. OHSF

96. Buchanan MR, Bertomeu M-C, Haas TA, Gallo S, Eltringham-Smith L. Endothelial cell 13-HODE synthesis and tumor cell endothelial cell adhesion. Adv Prostaglandin Thromboxane Leukot Res 21: 909-912, 1990. OHSF

95. Richardson M, Hatton MWC, Buchanan MR, Moore S. Wound healing in the media of the normolipemic rabbit carotid artery injured by air drying. Am J Pathol 137: 1453-1467, 1990. OHF

94. Van Ryn-McKenna J, Cai L, Ofosu FA, Hirsh J, Buchanan MR. Neutralization of enoxaparine-induced bleeding by protamine sulphate. Thromb Haemost 63: 271-274, 1990. OHF

93. Bertomeu M-C, Gallo S, Lauri D, Levine M, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 8: 511-518, 1990. OHF

92. Aznar-Salatti J, Bastida E, Buchanan MR, Castillo R, Ordinas A, Escolar G. Differential localization of von Willebrand factor, fibronectin and 13-HODE in human endothelial cell cultures. Histochemistry 93: 507-511, 1990. OHF

91. Bertomeu M-C, Crozier GL, Haas TA, Fleith M, Buchanan MR. Selective effects of dietary fats on vascular 13-HODE synthesis and platelet/vessel wall interactions. Thromb Res 59: 819-830, 1990. OHF

90. Haas TA, Bertomeu M-C, Bastida E, Buchanan, M.R. Cyclic AMP regulation of endothelial cell triglyceride turnover, 13-hydroxyoctadecadienoic acid (13-HODE) synthesis and endothelial cell thrombogenecity. Biochim Biophys Acta 1031: 174-178, 1990. OHF

89. Okwusidi J, Falcone M, Van Ryn-McKenna J, Hirsh J, Ofosu FA, Buchanan MR. In vivo catalysis of thrombin inhibition by antithrombin III and heparin co-factor II and antithrombotic effect: Differential effects of dermatan sulfate and unfractionated heparin. Thromb Haemorrh Disorders 1/2: 77-80, 1990. MRC

88. Cortelazzo S, Buchanan MR, Young E., Hirsh J, Anvari N, Van Ryn-McKenna J, Ofosu FA. Continuous infusion of low affinity heparin and dermatan sulphate induce the release into rabbit blood of a moiety which catalyses thrombin-antithrombin III formation. Thromb Haemorrh Disorders 1/2: 17-23, 1990. MRC

87. Andrew M, Ofosu FA, Brooker L, Buchanan MR. The comparison of the pharmacokinetics of low molecular weight heparin in the newborn and adult pig. Thromb Res 56: 529-539, 1990. OHF

86. Van Ryn-McKenna J, N'guyen P, Ofosu FA, Hirsh J, Buchanan MR. The effects of DDAVP on heparin induced bleeding. Thromb Haemorrh Disorders 1/2: 23-37, 1990. OHF

85. Lauri D, Bertomeu M-C, Orr FW, Bastida E, Sauder, D, Buchanan MR. Interleukin-1 increases tumor cell adhesion to endothelial cells through an RGD dependent mechanism: in vitro and in vivo studies. Clin Expt Metastasis 8: 27-32, 1990. MRC

84. Weber E, Haas TA, Mueller TH, Eisert WG, Hirsh J, Richardson M, Buchanan MR. Relationship between vessel wall 13-HODE synthesis and vessel wall thrombogenecity following injury. Influence of salicylate and dipyridamole treatment. Thromb Res 57: 383-392, 1990. OHF

83. Bastida E, Bertomeu M-C, Haas TA, Almirall L, Lauri D, Orr FW, Buchanan MR. Regulation of tumor cell adhesion by intracellular 13-HODE: 15-HETE ratio. J Lipid Mediator 2: 281-288, 1990. MRC

82. Buchanan MR. Inhibition of thrombosis by leukocytes: role of endogenous fatty acid metabolites. Sanofi Foundation for Thrombosis Research. Bulletin #4. IIIrd Sanofi Prix. 1989: pp.14-22. OHF

81. Ofosu FA, Buchanan MR, Anvari N, Smith LM, Blajchman MA. Plasma anticoagulant mechanisms of heparin, heparan sulfate and dermatan sulfate. Ann NY Acad Sci 556: 123-131, 1989. MRC

80. Bertomeu M-C, Buchanan MR. Vessel wall thrombogenecity and vascular surgery related thrombosis. Can J Cardiol 5 : vi, 1989. OHF

79. Ofosu FA, Birchall KJ, Buchanan MR. Preliminary report on a new approach to laboratory monitoring of the low molecular weight heparin CY 216. Thromb Haemost (Suppl): 35-40, 1989. MRC

78. Shaughnessy SG, Buchanan MR, Turple S, Richardson M, Orr FW. Walker Carcinosarcoma Cells Damage Endothelial Cells by the Generation of Reactive Oxygen Species. Am J Pathol 134: 787-796, 1989. MRC

77. Lauri D, Bertomeu M-C, Orr FW, Bastida E, Sauder DN, Buchanan MR. Differential effects of interleukin-1 and fMLP on chemotaxis and human endothelium adhesivity for A549 tumor cells. Lab Invest 60: 161-164, 1989. MRC

76. Van Ryn McKenna J, Buchanan MR. Relative effects of flurbiprofen on platelet 12-hydroxyeicosatetraenoic acid and thromboxane A2 production: influence on collagen induced platelet aggregation and adhesion. Prostaglandin Leuko Essent Fatty Acids 36: 171-174, 1989. OHF

75. Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Blajchman MA. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 257: 143-150, 1989. MRC

74. Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR . The antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulfation. Br J Haematol 71: 265-270, 1989. MRC

73. Van Ryn-McKenna J, Ofosu FA, Gray E, Hirsh, J, Buchanan MR. Effects of dermatan sulfate and heparin on inhibition of thrombus growth in vivo. Ann. NY Acad Sci 566: 304-312, 1989. MRC

72. Van Ryn-McKenna, J, Gray E, Weber E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 61: 7-9, 1989. MRC

71. Schmidt B, Buchanan MR, Ofosu FA, Brooker, L. Hirsh J, Andrew M. Antithrombotic properties of heparin in neonatal piglet model of thrombin induced thrombosis. Thromb Haemost 60: 289-292, 1988. OHF

70. Andrew M, Ofosu FA, Schmidt B, Brooker L, Hirsh J, Buchanan MR. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 52: 517-527, 1988. OHF

69. Haas TA, Bastida E, Nakamura K, Hullin F, Almirall L, Buchanan MR. Binding of 13-HODE, 5-, 12- and 15-HETE to endothelial cells and subsequent platelet, neutrophil and tumor cell adhesion. Biochem Biophys Acta 961: 153-159, 1988. OHF

68. Buchanan MR, Bastida E. Endothelium and underlying membrane reactivity with platelets, leukocytes and tumor cells: Regulation by the lipoxygenase-derived fatty acid metabolites, 13-HODE and HETE's. Med Hypothesis 27: 317-325, 1988. OHF

67. Haas TA, Buchanan MR. An automated extraction and quantification procedure for lipoxygenase metabolites. J Chromatogr 430: 1-10, 1988. OHF

66. Orr FW, Buchanan MR, Tron V, Guy D, Lauri D, Sauder DN. Chemotactic activity of endothelial cell derived interleukin 1 for human tumor cells. Cancer Res. 48: 6778-6763, 1988. MRC

65. Matzner Y, Cohn M, Hyam E, Razin E, Fuks Z, Buchanan MR, Haas TA, Vlodavsky I, Eldor A. Generation of lipid neutrophil chemoattractant by irradiated bovine aorta endothelial cells. J. Immunol 140: 2681-2686, 1988. OHF

64. Ofosu FA, Modi GJ, Blajchman MA, Buchanan MR, Johnson EA. Increased sulfation alters the anticoagulant activities of heparin, heparan sulfate, dermatan sulfate and chondroitin-4-sulfate. Biochem J 248: 889-896, 1987. OHF

63. Buchanan MR, Bastida E. The role of 13-HODE and HETE's in vessel wall/circulating blood cell interactions. Agents and Actions 22: 337-339, 1987. OHF

62. Buchanan MR, Richardson M, Haas TA, Hirsh J, Madri JA. The basement membrane underlying the vascular endothelium is not thrombogenic. Thromb Haemost 58: 698-704, 1987. OHF

61. Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 243: 579-588, 1987. MRC

60. Buchanan MR, Butt RW, Turpie AGG. Effect of nafazatrom on platelet function and release: relationship to symptomatic episodes in patients with peripheral vascular disease. Amer Heart J 113: 1133-1137, 1987. OHF

59. Boneu B, Buchanan MR, Caranobe C, Gabaig AM, Dupouy D, Sie P, Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res 46: 845-853, 1987. OHF

58. Boneu B, Caranobe C, Gabaig AM, Dupouy D, Sie P, Buchanan MR, Hirsh J. Evidence for a saturable and reversible mechanism of clearance of heparin in rabbits. Thromb Res 46: 835-844, 1987. OHF

57. Gibson BES, Buchanan MR, Barr RD, White JG. Primary thrombocythaemia in childhood: symptomatic episodes and their relationship to thromboxane A2, 6-keto-PGE1 and 12-hydroxy-eicosatetraenoic acid production: a case report. Prostaglandin Leuko Med 26: 221-231, 1987. OHF

56. Fernandez F, Buchanan MR, Hirsh J, Fenton JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating the antithrombotic potential of glycosaminoglycans. Thromb Haemost 57: 286-293, 1987. MRC

55. Ofosu FA, Modi GJ, Hirsh J, Buchanan MR, Blajchman MA. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides. Ann NY. Acad Sci 485: 41-55, 1986. MRC

54. Buchanan MR, Hirsh J. Effect of aspirin on hemostasis and thrombosis. N Eng Reg Allergy Pro 7: 26-31, 1986. OHF

53. Caranobe C, Petitou M, Dupouy D, Gabaig AM, Sie P, Buchanan MR, Boneu B. Heparin fractions with high and low affinities to antithrombin III are cleared at different rates: Influence of differential clearance on anticoagulant effect. Thromb Res 43: 635-641, 1986. OHF

52. Sie P, Ofosu FA, Fernandez F, Buchanan MR, Petitou M, Boneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various Sulphated polysaccharides. Brit J Haematol 64: 707-714, 1986. OHF

51. Fernandez F, Nguyen,P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43: 491-495, 1986. OHF

50. Andrew M, Ofosu FA, Fernandez F, Jefferies A, Hirsh J, Mitchell L, Buchanan MR. A low molecular weight heparin alters the fetal coagulation system in the pregnant sheep. Thromb Haemost 55: 342-346, 1986. OHF

49. Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematology 64: 309-317, 1986. MRC

48. Richardson M, Hatton MWC, Buchanan MR, Moore S. Scanning electron microscopy of normal rabbit aorta: injury or artifact? J Ultrastruct Res 91: 159-173, 1986. OHF

47. Buchanan MR, Butt RW, Hirsh J, Markham B, Nazir DJ. Role of lipoxygenase metabolism in platelet function: effect of aspirin and salicylate. Prostaglandin Leuko Med 21: 157-168, 1986. OHF

46. Ofosu FA, Fernandez F, Gauthor D, Buchanan MR . Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulphate. Semin Thromb Haemost 11: 133-137, 1985. MRC

45. Buchanan MR, Haas T, Lagarde M, Guichardant M. 13-Hydroxy-octadecadienoic acid is the vessel wall chemorepellant factor, LOX. J. Biol Chem 260: 16056-16059, 1985. OHF

44. Hirsh J, Ofosu FA, Buchanan MR. Rationale behind the development of low molecular weight heparin derivatives. Semin Thromb Haemost 11: 13-16, 1985. MRC

43. Agnelli G, Buchanan MR, Fernandez F., Hirsh J. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influences of Dosage Regimens. Thromb Res 40: 769-777, 1985. OHF

42. Agnelli G, Buchanan MR, Fernandez F, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood 66: 399-401, 1985. OHF

41. Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez F, Ofosu FA, Hirsh J. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombosis growth in vivo. Thromb Res 40: 81-89, 1985. OHF

40. Buchanan MR, Butt RW, Magas Z, Van Ryn J, Hirsh J, Nazir DJ. Endothelial cells produce a lipoxygenase derived chemorepellant which influences platelet/endothelial cell interactions: effect of aspirin and salicylate. Thromb Haemost 53: 306-311, 1985. OHF

39. Buchanan MR, Boneu B, Ofosu FA, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 65: 198-201, 1985. OHF

38. Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulfate, low molecular weight heparin and pentosan polysulfate. Brit J Haematol 60: 695-704, 1985. MRC

37. Agnelli G, Buchanan MR, Fernandez F, Boneu B, Van Ryn J, Hirsh J, Collen D. A comparison of the thrombolytic and hemorrhagic effects of tissue plasminogen activator and streptokinase. Circulation 72: 178-182, 1985. OHF

36. Andrew M, Boneu B, Cade JF, Cerskus AL, Hirsh J, Jefferies A, Towell M, Buchanan MR. Placental transport of low molecular weight heparin in the pregnant sheep. Brit J Haematol 59: 103-108, 1985. OHF

35. Buchanan MR, Hirsh,J. The effect of aspirin and salicylate on platelet/vessel wall interactions in rabbits. Atheriosclerosis 4: 403-406, 1984.

34. Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 35: 613-625, 1984.

33. Rosenfeld J, Buchanan MR, Reilly PA, Turpie AGG. Dipyridamole disposition after chronic administration: effect of aspirin. Thromb Res (Suppl) 4: 137-143, 1983.

32. Buchanan MR. Sulfinpyrazone: relationship between dose, kinetics, plasma concentrations and biological effect. Thromb Res (Suppl) 4: 89-92, 1983.

31. Buchanan MR, Endrenyi L, Giles AR, Rosenfeld J. The effect of aspirin on the pharmacokinetics of sulfinpyrazone in man. Thromb Res (Suppl) 4: 145-152, 1983.

30. Butt RW, Buchanan MR. Basal 6-keto-PGF1 levels: influence of sampling techniques. Thromb Res 29: 469-470, 1983.

29. Buchanan MR, Rischke JA, Butt R, Turpie AGG, Hirsh J, Rosenfeld J. The sex-related differences in platelet function and aspirin pharmacokinetics in rabbits and man. Thromb Res 29: 125-139, 1983.

28. Buchanan MR, Vazquez MJ, Gimbrone MA Jr. Arachidonic acid metabolism and the adhesion of human polymorphonuclear leukocytes to cultured vascular endothelial cells. Blood 62: 889-901, 1983.

27. Buchanan MR, Blajchman M, Hirsh J. Inhibition of arterial thrombosis and platelet function by Nafazatrom. Thromb Res 28: 157-170, 1982.

26. Rosenfeld J, Devereaux D, Buchanan MR, Turpie AGG. High performance liquid chromatography determination of dipyridamole. J. Chromatogr 231: 216-221, 1982.

25. Buchanan MR, Crowley CA, Rosin RE, Babior BM, Gimbrone MA. Studies on the Interaction between GP110-Deficient Neutrophils and vascular endothelium. Blood 60: 160-165, 1982.

24. Buchanan MR, Rischke JA, Hirsh J. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. Thromb Res 25: 363-374, 1982.

23. Buchanan MR, Dejana E, Gent M, Mustard JF, Hirsh J. Enhanced platelet accumulation onto injured carotid arteries in rabbits following aspirin treatment. J Clin Invest 67: 503-508, 1981.

22. Buchanan MR, Dejana E, Cazenave J-P, Richardson M, Mustard JF, Hirsh J. Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. Thromb Res 20: 447-460, 1980.

21. Buchanan MR, Blajchman MA, Dejana E, Mustard JF, Senyi AF, Hirsh J. Shortening of the bleeding time in thrombocytopenic rabbits after exposure of jugular vein to high aspirin concentrations. Prostaglandins Med. 13: 333-342, 1979.

20. Buchanan MR, Carter CJ, Hirsh J. Decreased platelet thrombogenecity in association with increased platelet turnover and vascular damage. Blood 54: 1369-1375, 1979.

19. Buchanan MR, Dejana E, Cazenave J-P, Mustard JF, Hirsh J. Uncontrolled PGI2 production by whole vessel wall segments due to thrombin generation in vivo and its prevention by heparin. Thromb Res 16: 551-555, 1979.

18. Buchanan MR, Rosenfeld J, Gent M, Lawrence W, Hirsh J. Increased dipyridamole plasma concentrations associated with salicylate administration. Relationship to effects in platelet aggregation in vivo. Thromb Res 15: 813-820, 1979.

17. Blajchman MA, Senyi AF, Hirsh J, Surya Y, Buchanan M. Mustard J.F. Shortening of the bleeding time in rabbits by hydrocortisone caused by inhibition of prostacyclin generation by the vessel wall. J Clin Invest 63: 1026-1035, 1979.

16. Buchanan MR, Rosenfeld J, Hirsh J. The prolonged effect of sulphinpyrazone on collagen-induced platelet aggregation in vivo. Thromb Res 13: 883-892, 1978.

15. Buchanan MR, Hirsh,J. A comparison of the effects of aspirin and dipyridamole on platelet aggregation in vivo and ex vivo. Thromb Res 13: 517-529, 1978.

14. Rosenfeld J, Buchanan M, Powers P, Hirsh J., Barnett HJM, Stuart RK. Determination of sulphinpyrazone in patient plasma by gas chromatography. Thromb Res 12: 247-255, 1978.

13. Kelton JG, Hirsh J, Carter CJ, Buchanan MR. Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest 62: 892-895, 1978.

12. Kelton JG, Hirsh J, Carter CJ, Buchanan MR. Sex differences in the antithrombotic effects of aspirin. Blood 52: 1073-1076, 1978.

11. Buchanan MR, Hirsh J. Assessment of antithrombotic drugs in vivo and ex vivo. Bibliotheca Anatomica, 16: 208-211, 1977.

10. Cade JF, Regoeczi E, Hirsh J., Buchanan MR. The effect of experimental hematoma on serum levels of fibrinogen-related antigen. Blood 47: 855-859, 1976.

9. Cade JF, Hirsh J, Regoeczi E, Gent M, Buchanan MR, Hynes DM. Resolution of experimental pulmonary emboli with heparin and streptokinase in different dosage regimens. J Clin Invest 54: 782-791, 1974.

8. Jorgensen L, Packham MA, Rowsell HC, Buchanan MR, Mustard J.F. Focal aortic injury caused by cannulation: Increased plasma protein accumulation and thrombosis. Acta Pathol Microbiol Scand 82: 637-647, 1974.

7. Kerrigan GNW, Buchanan MR, Cade JF. Regoeczi, E, Hirsh J. Investigation of the mechanism of false positive 125I-labelled fibrinogen scans. Br J Haematol 26: 469-473, 1974.

6. Reimers HJ, Buchanan MR, Mustard JF. Survival of washed rabbit platelets in vivo. Proc Soc Exp Biol Med 142: 1222-1225, 1973.

5. Jorgensen L, Hirsh J, Glynn MF, Buchanan MR, Mustard JF. Effect of streptokinase therapy on experimental fibrin-rich arterial thrombi. Am J Path 62: 7-12, 1971.

4. Jorgensen L, Glynn MF, Hovig T, Murphy EA, Buchanan MR, Mustard JF. Renal lesions and rise in blood pressure caused by adenosine diphosphate-induced platelet aggregation in rabbits. Lab Invest 23: 347-357, 1970.

3. Hirsh J, Buchanan M, Glynn MF, Mustard JF. Effect of activation of the fibrinolytic mechanism on experimental platelet-rich thrombi in rabbits. J Lab Clin Med 72: 245-255, 1968.

2. Hirsh J, Buchanan M, Glynn MF, Mustard JF. Effect of streptokinase on hemostasis. Blood 32: 726-737, 1968.

1. Glynn MF, Mustard JF, Buchanan MR, Murphy EA. Cigarette smoking and platelet aggregation. Can Med Assoc J 95: 549-553, 1966.

B O O K C H A P T E R

Buchanan MR Sex-related differences in the pathophysiology of CVD: Is there a rationale for gender-related treatments. Consensus Conference on Women and Ischemic Heart Disease. Can J Cardiol 17 (suppl D): 7D-13D, 2001.

50. Buchanan MR, Brister SJ. A rationale for targeting antithrombotic therapy at the vessel wall: Improved antithrombotic effect and decreased risk of bleeding. In: Wien Klin Wochenschr 111: 81 - 89, 1999.

49. Buchanan MR. Linoleic acid metabolites in health and disease. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury vol 4. KVHonn, LJ Marnett, S Nigam, E Dennis (eds), Kluwer Academic Publishers, Boston, 1999, pp 463 - 470.

489. Buchanan MR. Hemorrhage and hemostasis in tumours. In: J Cancer Prevention Control, In Press, 1998.

47. Buchanan MR. Fatty acid metabolism and blood cell/vessel wall interactions: Implications on current and future antithrombotic therapies. In: Mainzer Forums Medizinische Chemie 1993 und 1994, G Dannhardt, J Augustin (eds), Universitat Mainz Press, Mainz, 1995, pp 69-74.

46. Buchanan MR and Brister SJ. Endothelial cell 13-HODE and blood cell adhesion to the vessel wall. In: Adhesion Molecules and Cell Signalling: Biology and Clinical Applications. Topics in Molecular
Medicine Vol. 1. P.C. Weber, R Lorenz (eds). Raven Press Inc, New York, 1995, pp 169-178.

45. Brister SJ, Ofosu FA, Buchanan MR. Development and rationale for use of anti-thrombins in arterial thrombosis. In: THROMBIN: Key Role in Thrombogenesis - Implications for its Inhibition Clincally. MR Buchanan, SJ Brister, FA Ofosu (eds), CRC Press, Boca Raton, USA, 1994, pp 107-118.

44. Buchanan MR, Brister SJ, Ofosu, F.A. Heparin cofactor II and the prevention and treatment of thrombosis. In: THROMBIN: Key Role in Thrombogenesis - Implications for its Inhibition Clincally. MR Buchanan, SJ Brister, FA Ofosu (eds), CRC Press, Boca Raton, USA, 1994, pp 77-93.

43. Ofosu FA, Buchanan MR, Brister SJ. Thrombin-catalyzed amplification and inhibitory reactions of blood coagulation. In: THROMBIN: Key Role in Thrombogenesis - Implications for its Inhibition Clincally. MR Buchanan, SJ Brister, FA Ofosu (eds), CRC Press, Boca Raton, USA, 1994, pp 1-18.

41. Lafrenie RM, Buchanan MR, Orr FW. Adhesion molecules and their role in cancer metastasis. In: Cell Biophys, L Weiss (ed), Humana Press Inc., USA, 1994, pp 1-86.

40. Buchanan MR, Brister SJ. Other essential fatty acids, their metabolites and cell/cell interactions. The Handbook of Immunopharmacology: Lipid Mediators, pp 99-116, 1994.

39. BristerSJ, BuchananMR,Turpie AGG. Platelets in cardiopulmonary bypass. In: Blood Conservation '93. JE.Wynands (ed). Proc Can Anaesth Soc, Halifax, 1993, pp 1-5.

38. Ofosu FA, Buchanan MR. Profili farmacologici comparati dei glicosaminoglicani. Minerva Angiol 18:19-23, 1993.

37. Buchanan MR, Brister SJ, Ofosu FA. Integrita endoteliale. La perfezione necessaria: evoluzione delle conoscenze dalla fisiologia alla clinica. Minerva Angiol 18:11-18, 1993.

36. Buchanan MR, Brister SJ. "Heparinless" cardiopulmonary bypass (CPB): Novel strategies to avoid CPB related bleeding - Do they work? In: Blood Conservation '93. J.E. Wynands, (ed), Proc Can Anaesth Soc, Halifax, 1993, pp 11-18.

35. Buchanan MR, Brister SJ, Ofosu FA. Prevention and treatment of thrombosis: Novel strategies arising from our understanding the healthy endothelium. Wien Klin Wochenschr, 105/11:309-313, 1993.

34. Buchanan MR, Liao P, Ofosu FA. Relative effects of heparin and sulodexide on prevention of thrombin formation and growth. Importance of the heparin cofactor II pathway. Wiener Klinische Wochenschrift, In Press, 1993.

33. Buchanan MR, Brister SJ. Altering vessel wall fatty acid metabolism: A new strategy for antithrombotic treatment. Semin Thromb Haemost 19: 149-157, 1993.

32. Buchanan MR, Brister SJ, Bertomeu M-C. Eicosanoids, other fatty acid metabolites in the cardiovascular system: Are the present antithrombotic approaches rational? 5th International Symposium of Prostaglandins in the Cardiovascular System. HF Sinzinger, K Schror (ed) Birkhauser Verlag, 273-281, 1992.

31. Buchanan MR. Fatty acid metabolites and cancer: Provocative thoughts. In Cancer Chemoprevention. L Wattenberg, M Lipkin, CW Boone, GJ Kelloff (eds). CRC Press, Boca Raton, 1992:129-140.

30. Buchanan MR, Bertomeu M-C, Gallo S, Orr F W. Fatty acid regulation of endothelial cell adhesion molecules and tumor cell adhesion: Implications in Metastasis. In Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. S Nigam, K Honn, L Marnett, T Walden Jr. (eds). Kluwer Academic Publishers. 121:619-621, 1991.

29. Buchanan MR, Brister SJ. Changing vessel wall thrombogenecity as an alternative approach to antithrombotic therapy. Atherosclerosis IX, O Stein, S Eisenberg, Y Stein (ed). R&L Creative Communications Ltd., Tel Aviv 1992:535-538.

28. Buchanan MR, Bertomeu M-C, Crozier GL. Effetti selettivi dei grassi alimentari sulla sintesi del 13-HODE vascolare e sulle interazioni piastrine/parete vascolare. Focus on Endothelium and Vascular Disease. Vol. 1: 41-42, 1991.

27. Buchanan MR, Brister SJ. Antithrombotics and lipoxygenase pathway. In: Antithrombotics: pathophysiological rationale for pharmacological interventions, AG Herman (ed). Kluwer Academic Press Publishers, B.V. Inc. Dordrecht 1991, (9):159-179.

26. Buchanan MR, Bertomeu M-C, Haas TA. Fatty acid metabolism and cancer cell/endothelial cell interactions. In: Metastasis in the Microcirculation. MR Buchanan, FW Orr, L Weiss (ed). CRC Press. New York 1991, pp 217-237.

25. Buchanan MR, Bertomeu M-C. Endothelial cell function and metastasis. In: Metastasis in the Microcirculation. MR Buchanan, FW Orr and L Weiss (eds). CRC Press. New York 1991, pp 44-45.

24. Buchanan MR. Bertomeu M-C, Brister SJ, Haas TA. 13-Hydroxyoctadecadienoic 13-HODE metabolism and endothelial cell adhesion molecule expression: Effects on platelet vessel wall adhesion. Endothelium Thromboresistance, O Krapp, H Sinzinger (ed). Springer-Verlag, Wien Klin Wochenschr, 1991, 103/14: 416-421.

23. Buchanan MR, Bertomeu M-C, Brister SJ, Haas TA. Eicosanoid metabolism and endothelial cell adhesion molecule effects on platelet vessel wall interactions. Atherosclerosis: Cellular and Molecular Interactions in the Artery Wall. S Fedoroff, AI Gotleib, BL Langille (eds). Plenum Press, New York, NY, 1991, pp 227-233.

22. Buchanan MR, Bertomeu M-C, Bastida E, Orr FW, Gallo S. Eicosanoid metabolism and tumor cell endothelial cell adhesion. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. KV Honn, LJ Marnett, S Nigam, T Walden (eds) Kluwer Academic Publishers, Boston, 1991, pp 347-352.

21. Shaughnessy SG, Warner D, Buchanan MR, Lafrenie R, Orr FW. The Effects of oxygen radical - mediated pulmonary endothelial damage on cancer metastasis. In: Eicosanoids and other Bioactive Lipids in Cancer and Radiation Injury. KV Honn, LJ Marnett, S Nigam, T Walden (eds). Kluwer Academic Publishers, Boston, 1991, pp 147-152.

20. Buchanan MR, Bertomeu M-C. Preventative measures to reduce injured vessel wall thrombogenecity. In: Platelets and Atherosclerosis. Ch Kessler (ed). Springer-Verlag, Berlin, 1991, pp 31-38.

19. Buchanan MR. Megakaryocyte Platelet System: Structures and Function. In Clinical Hematology: Principles, Procedures, Correlations. CA Lotspeich, A Stiene-Martin, JA Koepke (eds). J.B. Lippincott Comp. Philadelphia USA, 1992, pp 653-670.

18. Buchanan MR, Bertomeu M-C, Bastida E. Fatty acid metabolism and cell/cell interactions. Agents Actions 29: 16-20, 1989.

17. Bertomeu M-C, Buchanan MR . Medikamentose reduktion der thrombogenitat geschadigter gefabwande. In Plattchen-Funktion und Gefabwand. Ch Kessler (ed). TM. Verlag, Hameln, FDR, 1989, pp 55-60.

16. Buchanan MR, Bastida E, Escolar G, Haas TA, Weber E. Vessel Wall Reactivity and 13-Hydroxy-octadecadienoic Acid Synthesis. In Advances in Prostaglandin Leuko Res 19: 293-298, 1989.

15. Buchanan MR, Ofosu FA, Van Ryn-McKenna J. Antithrombotic and hemorrhagic effects of dermatan sulfate. Int. Soc. Hematology. Book of Abstracts, Symposia and Oral Presentation. Milano, Italy, 1988. Sym., S-1-53.

14. Buchanan MR, Weber E, Richardson M. Cellular interactions at the blood vessel wall interface following injury: Possible antithrombotic role of polymorphonucleates. In: Biology of the Arterial Wall, D Haust, G Weber (eds), CIC Edizioni Internazionali: Siena, Italy, 1988, pp 69-76.

13. Ofosu FA, Buchanan MR, Anvari N. Plasma anticoagulant mechanisms of heparin, heparan sulfate and dermatan sulfate. N.Y. Acad. Sci., 556:123-133, 1988.

12. Buchanan MR . Mechanisms of pathogenesis of arterial thrombosis: potential sites of inhibition by therapeutic compounds. Semin Thromb Hemost 14: 33-40, 1988.

11. Buchanan MR, Crozier G, Haas TA. Fatty acid metabolism and the vascular endothelial cell: New thoughts for old data. In: Haemostasis, J van Mourik (ed). Karger, 1988; Vol. 18: 360-375.

10. Hirsh J, Buchanan MR, Ofosu FA, Weitz J. Evolution of thrombosis. Ann NY Acad Sci 516: 586-604, 1987.

9. Buchanan MR, Nakamura K, Haas TA, Hullin F. Endothelial blood cell interactions; role of fatty acid metabolites. In: Biology of Icosanoids in Blood and Vascular Cells. M Lagarde (ed). INSERM Symposia, Brussels, 1987, Vol. 152:247-258.

8. Buchanan MR, Ofosu FA, Fernandez F, Van Ryn J. Lack of relationship between enhanced bleeding induced by heparin and other sulphated polysaccharides and enhanced catalysis of thrombin inhibition. Semin Thromb. Hemost 12: 324-327, 1986.

7. Ofosu FA, Fernandez F, Gauthier D, Buchanan MR. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate. In: Seminars in Thrombos Hemost 11: 133-137, 1987.

6. Buchanan MR, Hirsh J. Effect of Aspirin on Hemostasis and Thrombosis. New England and Regional Allergy Proceedings: 7: 6-11, 1986.

5. Ofosu F, Buchanan MR, Hirsh J. Perspectives on the role of platelets in hemostasis. In: Hemostatic Mechanisms and Metastasis. KV Honn, BF Sloane (eds). Martinus Nijhoff Publishing, Boston US pp. 115-126, 1984.

4. Gimbrone MA Jr, Buchanan MR . Interactions of platelets and leukocytes with vascular endothelium: In vitro studies. Endothelium, AP Fishman (ed.). Ann NY Acad Sci 401: 171-183, 1983.

3. Buchanan MR, Rosenfeld J. A pharmacokinetic and pharmacodynamic approach to antithrombotic therapy: Thromb Res (Suppl iii) 1983.

4. Buchanan MR, Brister SJ., Ofosu FA. (editors). THROMBIN: Key Role in Thrombogenesis -Implications for its Inhibition Clinically" CRC Press, Boca Raton, USA, 1994.

3. Buchanan MR, Orr FW, Weiss L. (editors). Metastasis in the Microcirculation. CRC Press Inc., Boston, 1991.

2. Bastida E, Buchanan MR, Ofosu FA. A Rationale for the Development of Antithrombotic, Antimetastatic and Fibrinolytic Drugs: A Mechanistic Point of View. Thieme Medical Publishers Inc., New York, 1987.

1. Buchanan MR., Hirsh, J., Rosenfeld, J. (editors). A Pharmacokinetic and Pharmacodynamic Approach to Antithrombotic Therapy. Pergamon Press, New York, 1983.

A B S T R A C T S

Hamdulay Z, Verma S, Maganti M, Buchanan MR, El Ghoneimy Y, Brister SJ. Ethnic diversity: Comparison of outcomes after CABG in South Asian and Caucasian Canadian populations. Circ : , 2004

203 Buchanan MR, Brister SJ. The role of 13-hydroxyoctadecadienoic acid (13-HODE) in the prevention and diagnosis of cardiovascular disease. Proc Int’l Congr Atherothrom Haemost: Assisi, April, 2002.

202 Brister SJ Buchanan MR. The risk and benefit of hormone replacement therapy in women with cardiovascular disease. Proc Int’l Congr Atherothromb Haemost, Assisi, April 2002

201 Varghese R, Brister SJ, Buchanan MR. Plasma 13-HODE levels, cardiovascular disease (CAD) severity and thrombotic risk in patients undergoing coronary bypass grafting (CABG). Can J Cardiol 17 (suppl C): 435, 2001.

200 Cardin AD,Van Gorp CL, Buchanan MR, Eisenberg PR, Bailey BD, Muegge LH, Shetler TJ, Jackson CV. Intimatan inhibits acute coronary thrombosis in a canine medel of arterial injury. Thromb Haemost (Suppl): P1605, 2001.

199 Buchanan MR, Brister SJ, Cardin AD. Synergistic inhibition of thrombin-induced platelet aggregation by [Intimatan + Integrilin]: Implications for their clinical use. Thromb Haemost (Suppl): P1603, 2001.

198. Buchanan MR, Brister SJ. Inhibition of intimal hyperplasia and subsequent vessel wall occlusion after an acute oral treatment of 13-HODE in rabbits. Thromb Haemost (Suppl): P3076, 2001.

197. Brister SJ, Buchanan MR on behalf of the BRAT Investigators. Gender differences in cardiovascular disease (CVD and treatment practice in coronary artery bypass grafting (CABG) Can J Cardiol 16 (suppl): 236F, 2000.

196. Brister SJ, Prior P, Buchanan MR, Fedoryshyn J. Cardiac surgery and neurological dysfunction: The PUMP study - perfusion using multiple pumps Can J Cardiol 16 (suppl F): 123F, 2000.

195. Buchanan MR, Brister SJ. 13-HODE prevents vessel wall hyperplasia and facilitates arteriosclerotic lesion regression in rabbits following vessel wall injury. Can J Cardiol 16 (suppl F): 150F, 2000.

194. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston CM. The BRAT study results - Lack of an aspirin nonresponder effect. Can J Cardiol 15 (suppl D): 226D, 1999.

193. Yang LY, Cancel QV, Schwartz D, Abendschein D, Eisenberg PR,Van Gorp CL, Brister SJ, Buchanan MR. Intimatan, a heparin cofactor II catalyst, inhibits vessel wall thrombogenicity and intimal hyperplasia more effectively than heparin. Thromb Haemost 82 (suppl): 1311, 1999.

192. Buchanan MR, Maclean GA, Brister SJ. Evidence for a conformational change of surface-bound thrombin that promotes vessel wall thrombogenesis: Selective and sustained inhibition of its activity by Intimatan but not by heparin. Thromb Haemost 82 (suppl): 1309, 1999.

191. Buchanan MR, Schwartz L, Bourassa MG, Brister SJ, Peniston C. On behalf of the BRAT Investigators. Results of the BRAT Study - Benefits and risks of aspirin on thrombosis in patients undergoing coronary artery bypass surgery - Lack of an aspirin nonresponder effect. Thromb Haemost 82 (suppl): 200, 1999.

190. Van Gorp CL, Buchanan MR, Brister SJ, Linhardt RJ. Dermatan disulfate, an inhibitor of thrombin generation and complement activation. US Patent # 5,922,690, 1999.

189. Buchanan MR, Van Gorp CL, Griffin CC, Linhardt RJ, Brister SJ. Systemic and surface-bound thrombin activity: Implications for the assessment of the anticoagulant and antithrombotic effects of heparin, dermatan sulfate and Intimatan. Haemost 28 (suppl 2): 99, 1998.

188. Buchanan MR, Brister SJ. Surface-bound thrombin inhibition and intimal hyperplasia: Relative effects of heparin and Intimatan. Haemost 28 (suppl 2): 4, 1998.

187. Buchanan MR, Brister SJ, Turpie AGG. Ticlopidine as an alternate antiplatelet agent for aspirin nonresponders. Can J Cardiol Oct 1997, In Press.

186. Buchanan MR. Linoleic acid metabolites in health and disease. Proc 5th Intl Conf Eicosaoids & Other Bioactive Lipids in Cancer, Inflammation and related Diseases. La Jolla, USA, Sept 1997, In Press.

185. Popovski Z, Buchanan MR, Hudson P, MacKenzie M, Brister SJ. Economic evaluation of epsilon-aminocapoic acid in cardiac surgery patients. Proc 7th World Congr Inten Crit Care Med. Ottawa, July, 1997

184. Brister SJ, Buchanan MR. Inhibition of surface-bound thrombin by dermatan sulphate during cardiopulmonary bypass in pigs: Advantages over heparin. Thromb Haemost 76 (suppl): PS-1205, 1997.

183. Brister SJ, Buchanan MR. Decreased vessel wall thrombogenicity following linoleic acid supplementation in patients undergoing coronary artery bypass grafting. Thromb Haemost 76 (suppl): PS-1339, 1997.

182. Buchanan MR, Brister SJ. Chronic restenosis can be inhibited with acute antithrombotic therapy: Implications in (cardio)vascular procedures. Thromb Haemost 76 (suppl): PS-525, 1997.

181. Buchanan MR, Brister SJ, Peniston CM, Schwartz L, Leclerc Y, Bourassa MG for the BRAT Investigators. There is no rationale for stopping aspirin before cardiac surgery. Thromb Haemost 76 (suppl): PS-320, 1997.

180. Blake JM, Buchanan MR, Cunnington J, Norman GR, Keane D. Impact of a reliable formative evaluation of student progress on student behaviour. Proc. 7th Ottawa Conf Med Educ Assess, Maastricht, The Netherlands, June 25-28, 1996

179. Brister SJ, Buchanan MR. Successful cardiopulmonary bypass (CPB) in pigs anticoagulated with dermatan sulfate: Advantages over heparin. Circulation 94 (Suppl): I-742,1996.

177. Buchanan MR, Brister SJ. Chronic restenosis can be attenuated by acute antithrombotic treatment at the time of injury: Implications in (cardio)vascular procedures. Haemostasis 26 (Suppl 3): 23, 1996.

176. Brister SJ, Buchanan MR, Griffin CC, Linhardt RJ, Van Gorp CL. Effects of heparin and CL-03135 on complement activation in vitro and thrombin generation during cardiopulmonary bypass (CPB) in vivo. Haemostasis 26 (Suppl 3): 131, 1996.

175. Buchanan MR, Brister SJ, Finkle C, DiMaio J, Winocour PD. Inhibition of thrombin generation and platelet activation during cardiopulmonary bypass (CPB) in pigs: Relative effects of the direct thrombin inhibitor,BCH 2763, and heparin. Haemostasis 26 (Suppl 3): 575, 1996.

174. Brister SJ, Buchanan MR. Dermatan Sulphate: An alternative to heparin for cardiac surgery. Can J Cardiol. 12 (Suppl E): 112E, 1996.

173. Buchanan MR, Brister SJ. Inhibition of chronic restenosis with acute antithrombotic therapy. Can J Cardiol. Oct. 12 (Suppl E): 147E, 1996.

172. Brister SJ, Buchanan MR. Effects of linoleic acid supplements on vessel wall thromboresistance in patients undergoing cardiac surgery. Prost. Leuko. & Essential Fatty Acids, 55 (Suppl 1): 48, 1996.

171. Buchanan MR, Brister SJ. Effects of 13-HODE and other monohydroxides on integrin/ligand binding: Implications for cell cell interactions. Prost. Leuko. & Essential Fatty Acids, 55 (Suppl 1): 48,1996.

170. Buchanan MR, Brister SJ. Inhibition of injured vessel wall restenosis with acute thrombin inhibition: Relative effects of heparin and dermatan sulphate. Abstract Book, Joint Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Salt Lake City, UT, Feb 18-20, 1996, P17.

169. Buchanan MR, Brister SJ, Schwartz L, Peniston CL, Leclerc Y, Bourassa MG on behalf of the BRAT Investigators. The benefits and risks of ASA in thrombosis. Can Cardiovasc Soc Meeting, Toronto, Oct'95.

168. Young W, Kang J, Gawad Y, Stanton E, Turpie A, Buchanan M, Takahashi, M, Jackowski G, Skea D. Rapid format assay for the detection of anti-streptokinase antibody in human blood. Am Assoc Clin Chem, Anaheim, July, 1995.

167. Buchanan MR, Brister SJ. Increasing vessel wall (VW) 13HODE metabolism with dietary fatty acid supplements in patients undergoing cardiac surgery decreases VW reactivity to platelets. Can J Cardiol 10 (Suppl C): 67C, 1994.

166. Gawad YA, Skea D, Takahashi M, Tanser PH, Stanton EB, Sayles MJ, Turpie AG, Buchanan MR, Jackowski G. Development and evaluation of an assay specific for human anti-streptokinase antibodies (lgG). Clin Chem 40: 991, 1994.

165. Levely A, Macdonald W, Hamilton M, Brister SJ, Buchanan MR. CPB pumps and thrombin generation - what goes around comes around. Proceed Can Perf Soc, Edmonton, October 27, 1994.

164. Brister SJ, Buchanan MR, Horrobin D. Altering vessel wall 13-HODE and vessel wall reactivity with dietary fatty acid supplements in patients undergoing cardiac surgery. Bk of ABSTs, VIIIth Intl Symp Biol Vasc Cell, Heidelberg, August 30, 1994, pp 150.

163. Buchanan MR, Wale C, Smith LJ, Gallo S, Lafrenie RM, Haas TA. Regulation of vitronectin receptor ligand binding by the 15-lipoxygenase monohydroxides, 15-HETE and 13-HODE. Bk of ABSTs, VIIIth Intl Symp Biol Vasc Cells, Heidelberg, August 30, 1994, pp 151.

162. Brister SJ, Ofosu FA, Buchanan MR . Advantages of using dermatan sulfate instead of heparin during cardiopulmonary bypass (CPB). Can J Cardiol 10 (Suppl C): 84C, 1994.

161. Low AM, Kebache R, Gallo S, Buchanan MR, Kwan CY, Daniel EE. Tyrosine kinase regulates dihydropyridine-insensitive Ca2+ entry following depletion of Ca2+ stores or receptor agonist stimulation. 8th Intl Symposium on Vascular Neuro Mech, Kananaskis Village, Alberta, August 1-4, 1994.

160. Low AM, Gallo S, Buchanan MR, Daniel EE. Tyrosine kinase inhibitors enhance K+ currents in human endothelial cells. XII Cong Intl Pharm, January 1994.